Phenotypes Associated with This Genotype

Genotype
MGI:5603596

hm2

• Allelic Composition: Insm1^{tm1.1(GFP/cre)Mgn}/Insm1^{tm1.1(GFP/cre)Mgn}
• Genetic Background: involves: 129S6/SvEvTac * CD-1 * SJL

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

lethality throughout fetal growth and development ( J:214095 )

• die between E15.5 and E18.5, with about 10% surviving to E18.5

endocrine/exocrine glands

abnormal endocrine pancreas morphology ( J:214095 )

• only 8% of GFPCre-expressing endocrine cells are insulin positive at E18.5 and there is a decrease in cells expressing glucagon (from 24% to 11%), somatostatin (from 11% to 7%) and ghrelin (from 8% to 5%), indicating a possible defect in hormone production

• number of pancreatic polypeptide-positive cells is increased from 7% to 12% at E18.5

abnormal endocrine pancreas development ( J:214095 )

• size of the endocrine progenitor cells is increased at E18.5 and their shape becomes irregular

• endocrine progenitor cells are less differentiated

abnormal pancreatic endocrine progenitor cell physiology ( J:214095 )

• endocrine cells remain closely associated with pancreatic ductal cells, indicating a defect of differentiating pre-endocrine cells to migrate away from pancreatic ductal regions

decreased pancreatic endocrine progenitor cell proliferation ( J:214095 )

• endocrine progenitor cells show a slight decrease in proliferation (from 1.4% to 0.9%) at E15.5 and up to a 7-fold decrease at E18.5

cellular

decreased pancreatic endocrine progenitor cell proliferation ( J:214095 )

• endocrine progenitor cells show a slight decrease in proliferation (from 1.4% to 0.9%) at E15.5 and up to a 7-fold decrease at E18.5